Editorial: New Insights on Bruton's Tyrosine Kinase Inhibitors
- PMID: 34887877
- PMCID: PMC8650313
- DOI: 10.3389/fimmu.2021.804735
Editorial: New Insights on Bruton's Tyrosine Kinase Inhibitors
Keywords: BTK; Waldenström’s macroglobulinemia; autoimmunity; ibrutinib; inhibitors; leukemia; lymphoma; structure-function.
Conflict of interest statement
JB has served as a consultant for Abbvie, Acerta/Astra-Zeneca, Beigene, Bristol-Myers Squibb/Juno/Celgene, Catapult, Genentech/Roche, Eli Lilly, Janssen, MEI Pharma, Morphosys AG, Nextcea, Novartis, Pfizer, Rigel; received research funding from Gilead, Loxo/Lilly, Verastem/SecuraBio, Sun, TG Therapeutics; and served on the data safety monitoring committee for Invectys. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Comment on
- Editorial on the Research Topic New Insights on Bruton’s Tyrosine Kinase Inhibitors
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
